Quantum BioPharma is reporting preliminary clinical results that indicate that a novel PET tracer for imaging demyelination in multiple sclerosis (MS) shows signal in acute MS lesions and potential sensitivity to gray matter lesions.
The early data come from an ongoing collaborative study with Massachusetts General Hospital (MGH) evaluating F-18 3F4AP, a tracer developed by MGH investigators, for its ability to directly detect demyelinated neurons with intact axons. The study has reached the halfway enrollment mark, the company said.
If validated, the imaging approach could be used to measure how therapies affect myelin preservation and regeneration, Quantum noted. The company is also developing Lucid-MS, an investigational MS treatment targeting myelin degradation, with a phase II investigational new drug submission filed with the U.S. Food and Drug Administration (FDA) in March 2026.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
